Etiome

Executive Summary

Etiome is a San Diego-based biotechnology company pioneering a novel class of 'Biostaged Medicines' that aim to intervene in disease before it becomes debilitating. By leveraging single-cell omics and artificial intelligence, the company models the molecular progression of diseases to identify stage-specific therapeutic targets and biomarkers. This preemptive healthcare approach seeks to deliver the right medicine to the right patient at the right biological moment. Founded in 2021, Etiome operates at the intersection of AI and precision medicine, with a focus on understanding disease trajectories at the single-cell level. The company's platform holds promise for transforming the treatment paradigm for chronic and degenerative diseases, potentially enabling earlier, more effective interventions. As a private company with no disclosed funding or valuation, Etiome is in an early development phase, but its innovative concept and strong scientific foundation position it well for future growth. The company's vision aligns with broader trends toward personalized medicine and AI-driven drug discovery, suggesting significant potential if it can successfully translate its platform into validated therapeutic candidates.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Round70% success
• Q4 2026Preclinical Proof-of-Concept Data Release for Lead Program60% success
• Q1 2027Strategic Partnership with Pharma or AI Platform Collaborator50% success